Physician profile
Sumit Saini
NPI 1528710514
$896.39
in general payments reported to CMS, 2019-2025
12 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $611 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $151.40 | 2025 | |
| Boston Scientific Corporation | $146.39 | 2023 | Lithovue, Spaceoar Vue System - 10ml |
| Bayer Healthcare Pharmaceuticals INC. | $143.15 | 2023 | |
| Merck Sharp & Dohme LLC | $125.00 | 2023 | Lynparza |
| Intuitive Surgical, INC. | $103.28 | 2025 | |
| Photocure INC | $62.40 | 2023 | Cysview |
| Karl Storz Endoscopy-America | $62.40 | 2023 | Hopkins |
| Calyxo, INC. | $30.38 | 2025 | Cvac Aspiration System |
| Janssen Biotech, INC. | $21.00 | 2023 | Erleada |
| Sumitomo Pharma America, INC. | $19.36 | 2023 | Gemtesa |
| Dendreon Pharmaceuticals LLC | $15.90 | 2023 | Provenge |
| Myriad Genetic Laboratories, INC. | $15.73 | 2023 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.